Preclinical NAMs
Bon3OID in vitro models for preclinical research
CompagOs supports efficacy assessment and mechanistic insight with human-relevant bone models that capture mineralization, remodeling, and disease-specific response.
NAMs (New Approach Methodologies) are human-relevant in vitro and in silico methods intended to reduce reliance on animal models while improving translational relevance. CompagOs applies NAMs to bone biology and preclinical development workflows.
Osteoblast Model (Bon3OID)
Mineralized bone model with osteoblasts and osteocytes for anabolic bone-targeting agents and efficacy testing.
Bone Remodelling Model (Bon3OID-OC)
Includes osteoblasts, osteoclasts, and osteocytes for functional assessment and mechanistic insight.
Customized Models
Tailored disease phenotypes, cancer cell seeding, or specific readouts for specialized preclinical needs.
Custom Models
Tailored disease phenotypes and cell types
We can build models for rare bone diseases, oncology indications, or specific mechanistic questions by incorporating patient-derived cells or additional cell lines.
- Featured models include osteogenesis imperfecta and osteosarcoma.
- Current focus: bone metastasis niche and critical-sized defect healing.
- Special requests: multiple myeloma or other bone diseases.
Readouts
Cutting-edge assessment methods
Micro-CT
Stiffness measurement
Histology and staining
Start your Bon3OID study
Share your indication, target, and readout needs. We will shape the right model and timeline together.